Background
B-cell maturation antigen (BCMA) is the main target for chimeric antigen receptor (CAR)-T cells in multiple myeloma (MM), demonstrating promising outcomes. However, unlike what happens with CART19 in lymphoblastic leukemia and non-Hodgkin’s…
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype characterized by limited treatment options and poor prognosis. Immune checkpoint blockade, particularly via programmed cell death protein-1/programmed death-ligand 1 inhibitio…
Background
Most colorectal cancers (CRCs) are mismatch repair-proficient (pMMR) and microsatellite stable (MSS), and they respond poorly to immune checkpoint inhibitors (ICIs). Radiotherapy (RT) can promote antitumor immunity but may also trigger adap…
Background
Global clinical programs based on TIGIT (T cell immunoglobulin and ITIM domain) blockade have been terminated due to inadequate clinical efficacy. New approaches are needed to increase the antitumor activity of anti-TIGIT-based immunotherap…
Abstract
T cell engagers (TCEs) recruit T cells to the tumor microenvironment (TME) to induce antitumor immune responses. TCEs have demonstrated promising clinical responses in patients with metastatic castration-resistant prostate cancer and have adv…
Background
At diagnosis, ~80% of pancreatic ductal adenocarcinomas (PDAC) have metastasized. Relapse is thus common even among patients who undergo surgical resection, the only curative option. PDAC progresses rapidly, and existing immunotherapies hav…
Background
The complex tumor microenvironment (TME) of colorectal cancer (CRC), composed of diverse cellular components and dynamic interactions, constitutes a major barrier to effective immunotherapy and facilitates disease progression. There is a pr…
Adoptive transfer of unmodified T cells has shown limited clinical benefit, prompting a shift toward chimeric antigen receptor (CAR) engineering to enhance activation, persistence, and tumor specificity. CAR technology positions T cells as promising…
Tumor-associated macrophages are key myeloid cells in the tumor microenvironment (TME), acting as essential orchestrators of innate and adaptive immune responses. The efficacy of current antitumoral treatments can be promoted by macrophages, thanks to…
Objective
Metadherin (MTDH) is a recognized oncogene involved in the progression and metastasis of various cancers. However, further studies are needed to elucidate the biological role of MTDH, which is expressed in macrophages during tumor progressio…
